BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25054891)

  • 1. Bevacizumab therapy for glioblastoma: a passionate discussion.
    Desjardins A; Friedman HS
    CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
    [No Abstract]   [Full Text] [Related]  

  • 2. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
    Stupp R; Weller M
    Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab in glioblastoma--still much to learn.
    Fine HA
    N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Sulman EP; Mehta MP
    N Engl J Med; 2014 May; 370(21):2048-9. PubMed ID: 24849088
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?
    Chamberlain MC
    CNS Drugs; 2011 Oct; 25(10):815-8. PubMed ID: 21936584
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Cloughesy T
    N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab for newly diagnosed glioblastoma.
    Haines IE; Gabor Miklos GL
    N Engl J Med; 2014 May; 370(21):2048. PubMed ID: 24849089
    [No Abstract]   [Full Text] [Related]  

  • 8. Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?
    D'Alessandris QG; Capo G; Pallini R
    Neuro Oncol; 2014 Oct; 16(10):1427. PubMed ID: 25053854
    [No Abstract]   [Full Text] [Related]  

  • 9. Predicting glioblastoma response to bevacizumab through marker profiling?
    Kessler T
    Neuro Oncol; 2016 Feb; 18(2):149-50. PubMed ID: 26803809
    [No Abstract]   [Full Text] [Related]  

  • 10. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
    Piccioni DE; Lai A
    Neuro Oncol; 2014 Oct; 16(10):1427-8. PubMed ID: 25155359
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?
    Marosi C
    CNS Oncol; 2013 Nov; 2(6):473-4. PubMed ID: 25054815
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
    Malkki H
    Nat Rev Neurol; 2014 Apr; 10(4):179. PubMed ID: 24638136
    [No Abstract]   [Full Text] [Related]  

  • 13. Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.
    Lomax AJ; Yannakou CK; Rosenthal MA
    Target Oncol; 2013 Jun; 8(2):153-5. PubMed ID: 23430346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
    Lukas RV; Goldenberg F; Nicholas MK
    J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
    Clarke JL
    Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
    Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
    Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy of brain tumors: the role of bevacizumab.
    Trevisan E; Bertero L; Bosa C; Magistrello M; Pellerino A; Rudà R; Soffietti R
    Neurol Sci; 2014 Apr; 35(4):507-14. PubMed ID: 24442487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to T.J. Kruser et al.
    Chinot OL; Taphoorn MJ; Bais C; Bourgon R; Phillips HS; Abrey LE; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Cloughesy T
    J Clin Oncol; 2016 Apr; 34(11):1282-3. PubMed ID: 26884575
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
    Kruser TJ; Mehta MP; Kozak KR
    J Clin Oncol; 2016 Apr; 34(11):1281-2. PubMed ID: 26884565
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.